Publikationsliste PD Dr. med. Mathias Schmid. Impact Faktoren gesamt: 237,126 Impact Faktoren Erst-/Letztautor gesamt: 86,962

Transcription

1 Publikationsliste PD Dr. med. Mathias Schmid Impact Faktoren gesamt: 237,126 Impact Faktoren Erst-/Letztautor gesamt: 86,962 Originalarbeiten 1. Digel, W., Schöniger, W., Stefanic, M., Janssen, H., Buck, C., Schmid, M., Raghavachar, A., and Porzsolt, F. Receptors for TNF on neoplastic B-cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. Blood, 76, , Impact Faktor: Digel, W., Schmid, M., Heil, G., Conrad, P., Gillis, S., and Porzsolt, F. Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood, 78, , Impact Faktor: Digel, W., Porzsolt, F., Schmid, M., Herrmann, F., Lesslauer, W., and Brockhaus, M. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J. Clin. Invest., 89, , Impact Faktor: 15, Schmid, M., Merk, B., and Porzsolt, F. Cyclosporin A (CsA) inhibits cytokine-induced proliferation in B-chronic lymphocytic leukemia. Leukemia and Lymphoma, 15: , 1994 Impact Faktor: 2, Porzsolt, F., Schmid, M., Staib, G., and Schrezenmaier, H. Paracrine regulation of B-cell growth in hairy cell leukemia. Leukemia and Lymphoma, 14 (Suppl.1), 13-18, Impact Faktor: 2, Porzsolt, F., Schmid, M., Höher, D., Muche, R., Gaus, W., and Montenarh, M. Biologic relevance of auto-antibodies against p53 in patients with metastatic breast cancer. Onkologie, 17, , Impact Faktor: 1, Schmid, M., Schrezenmaier, H., Staib, G., and Porzsolt, F. Evidence for a paracrine pathway of B-cell stimulation in hairy cell leukemia. Br. J. Haematol., 90: , Impact Faktor: 4,597

2 8. Demeter, J., Schmid, M., Vargha, P., and Porzsolt, F. Correlation of elevated plasma soluble IL-2 receptor levels with defective NK- and CD8+ T-cells in myelodysplastic syndromes: is it part of a spectrum? Leukemia Res., 19:18-19, [letter to the editor]. Impact Faktor: 2, Demeter, J., Schmid, M., and Porzsolt, F. Observations regarding hairy cell leukemia and chronic lymphocytic leukemia within the proposed new classification of lymphoid neoplasms. Blood, 85: , [letter]. Impact Faktor: Demeter, J., Messer, G., Rämisch, S., Mee, J.B., di Giovine, F.S., Schmid, M., Herrmann, F., and Porzsolt, F. Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies. Cytokines Mol. Ther., 2, , Impact Faktor: 0, Demeter, J., Porzsolt, F., Rämisch, S., Schmidt, D., Schmid, M., and Messer, G. Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br. J. Haematol., 97, , Impact Faktor: 4, Demeter, J., Porzsolt, F., Rämisch, S., Schmid, M., Messer, G. Polymorphism of the tumour necrosis factor-alpha and lymphotoxinalpha genes in hairy cell leukaemia. Br J Haematol, 97, , Impact Faktor: 4, Schmid, M., Malicki, D., Nobori, T., Rosenbach, M.D., Campbell, K., Carson, D.A., and Carrera, C. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than homozygous p16 INK4A deletions in non-small cell lung cancer (NSCLC). Oncogene, 17, , Impact Faktor: 7, Brat, D.J., James, C.D., Jedlicka, A.E., Connolly, D.C., Chang, E., Castellani, R.J., Schmid, M., Schiller, M., Carson, D.A., and Burger, P.C. Molecular genetic alterations in radiation-induced astrocytomas. Am J Pathol, 154, , Impact Faktor: 5,673

3 15. Konig, E.A., Kusser, W., Day, C., Porzsolt, F., Glickman, B., Messer, G., Schmid, M., de Chatel, R., Marcsek, Z.L., and Demeter, J. p53 mutations in hairy cell leukemia. Leukemia, 14: , Impact Faktor: 8, Schmid, M., Sen, M., Rosenbach, D., Carrera, C.J., Friedman, H., and Carson, D.A. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. Oncogene, 19: , Impact Faktor: 7, Hübinger, G., Schmid, M., Linortner, S., Manegold, A., Bergmann, L., and Maurer, U. Ribozyme-mediated clevage of WT1 transcripts suppresses cell growth of leukemia cells associated with the induction of p21 cip/waf1. Exp. Hematology, 29: , Impact Faktor: 3, Hübinger, G., Schneider, C., Stöhr, D., Ruff, H., Kirchner, D., Schwänen, C., Schmid, M., Bergmann, L., and Müller, E. CD30-induced upregulation of the inhibitor of apoptosis genes ciap1 and ciap2 in anaplastic large cell lymphoma cells (ALCL). Exp. Hematology, 32: , Impact Faktor: 3, Mihailovic T, Marx M, Auer A, Van Lint J, Schmid M., Weber C, Seufferlein T. Protein kinase D2 mediates activation of nuclear factor kappab by Bcr-Abl in Bcr-Abl+ human myeloid leukemia cells. Cancer Res., 64: , Impact Faktor: 7, Liebisch, P., Eppinger, S., Schöpflin, C., Stehle, G., Munzert, G., Döhner, H., and Schmid, M. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica/The Hematology Journal, 90: , Impact Faktor: 6, Kuendgen, A., Schmid, M., Schlenk, R., Knipp, S., Hildebrandt, B., Steidl, C., Germing, U., Haas, R., Dohner, H., and Gattermann, N. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer, 106:112-9, Impact Faktor: 5,418

4 22. Schneider, L.A., Schmid, M., Staib, G., Weiss, t., Scharffetter- Kochanek, K., and Weber, L. Cutaneous infiltrations can herald an inapparent myelodysplastic syndrome. Acta Derm. Venerol., 86: , Impact Faktor: 3, Heimpel, H., Schwarz, K., Ebnöther, M., Goede, J.S., Heydrich, D., Kamp, T., Plaumann, L., Rath, B., Roessler, J., Schildknecht, O., Schmid, M., Wuillemin, W., Einsiedler, B., Leichtle, R., Tamary, H., and Kohne, E. Congenital dyserythropoietic anemia type I (CDA I): molecular genetics, clinical appearance, and prognosis based on long-term observation. Blood, 107: , Impact Faktor: 10, Wassmann, B., Pfeifer, H., Goekbuget, N., Beelen, D.W., Beck, J., Stelljes, M., Bornhäuser, M., Reichle, A., Perz, J., Haas, R., Ganser, A., Schmid, M., Kanz, L., Lenz, G., Kaufmann, M., Binckebanck, A., Brück, P., Reutzel, R., Gschaidmeier, H., Schwartz, S., Hoelzer, D., Ottmann, O.G. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood, 108: , Impact Faktor: 10, Schmid, M. Iron chelation therapy in MDS: what have we learnt recently? Blood Reviews, 23:S21-S25, Impact Faktor: 7, Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C., Silverman, L.R., Durrant, S., Enno, A., Herrmann, R., Horvath, N., Mills, A., Spencer, A., Szer, J., Gallo, J., Dunlop, L., Arthur, C., Goranov, S., Peytchev, D., Gercheva, L., Cermak, J., Voglova, J., Vey, N., Dreyfus, F., Laurent, G., Quesnel, B., Dombret, H., Stamatoullas, A., Wattel, E., Hunault-Berger, M., Aul, C., Duhrsen, U., Platzbecker, U., Schmid, M., Hanel, M., Haase, D., Fiedler, W., Schmitz, N., Hofmann, W., Horst, H., Anagnostopoulos, N., Pappa, V., Papadaki, E., Zoumbos, N., Borbenyi, Z., Masszi, T., Baccarani, M.,

5 Bacigalupo, A., Corradini, P., Leone, G., Sacchi, S., Bosi, A., Musto, P., Muus, P., Dmoszynska, A., Robak, T., Sulek, K., Kuliczkowski, K., Jedrzejczak, W., Zaritsky, A., Abdulkadyrov, K., Podoltseva, E., Afanasiev, B., Bargay, J., Brunet, S., Del Canizo, C., Ribera, J., Figuera Alvarez, A., Diaz-Mediavilla, J., Canales, M., Ramos y Ortega, F., Nilsson, L., Olsson, A., Cavenagh, J., Parker, J., Killick, S., Kruger, A., Vyas, P., Dennis, M., Cripe, L., DiPersio, J., Emanuel, P. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10: , Impact Faktor: 14, Schmid, M. Resultados clínicos del tratamiento con deferrasirox en pacientes con SMD. Haematologica (Spanish Ed.), 94:27-28, Impact Faktor: 6, Bernhardt, P., Imhof, A.,, Schwaab, J., Balbach, J., Walcher, D., Jochen Spieß, J., Schmid, M. Neoplastic pericardial effusion induces functional nonvalvular mitral valve stenosis. J Am. Coll. Card., 56:e29, Impact Faktor: 12, Bullinger L, Lupo T, Stegelmann F, Griesshammer M, Döhner K, Schmid M. Response to Class prediction models of thrombocytosis using genetic biomarkers. [e-letter], Blood (115/1/7#121). April 15, Impact Faktor: Gattermann, N., Finelli, C., Della Porta, M., Fenaux, P., Ganser, A., Guerci-Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., Domokos, G., Roubert, B., and Rose, C. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk. Res, 34(9), , Impact Faktor: 2, Ellegast, J., Barth, T.F.E., Schulte, M., Bielack, S.S., Schmid, M., and Mayer-Steinacker, R. Metastasis of osteosarcoma after 16 years. J. Clin. Oncol., Nov. 22, 2010 Impact Faktor: 17,793 (Epub ahead of print equal contribution).

6 32. Lee, J.W., Yoon, S.S., Shen, Z.X., Ganser, A., Hsu, H.C., Habr, D., Domokos, G., Roubert, B., Porter, J.B., and EPIC study investigators. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood, 116: , Impact Faktor: Bommer, M., Nagy, A., and Schmid, M. Cerebrospinal fluid pleocytosis - pitfalls and benefit of combined analysis using cytomorphology and flow cytometry. Cancer Cytopathol (in press) Impact Faktor: 2,471 Übersichtsartikel: 1. Schmid, M., and Porzsolt, F. Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia. Leukemia and Lymphoma, 17: , Impact Faktor: 2,397 Kasuistiken: 1. Beck, C., Humpe, A., Harder, S., Schmid, M., and Horst, H.A. Myelodysplastic syndrome of donor origin subsequent to successful treatment of myeloid/nk-cell precursor leukemia with allogeneic PBSCT: two very rare conditions in one patient. Ann. Hematol., 84: , Impact Faktor: 2,919 Buchbeiträge: 1. Heimpel, H., and Schmid, M. (1996) Interferon-alpha: Clinical utility and future perspectives of therapeutic action. In Aul (Ed.) Interferons - Biological activities and clinical efficacy. pp (Springer Verlag). 2. Schmid, M., and Carson, D.A. Cell cycle regulation in hematological disorders. In Beutler, E. et al. (Eds.):Williams Hematology 6 th Edition (McGraw Hill BK CO), pp , Schmid, M., and Carson, D.A. Cell cycle regulation in hematological disorders. In Beutler, E. et al. (Eds.):Williams Hematology 7 th Edition (McGraw Hill BK CO), pp , 2005.

7 4. Schmid, M., and Carson, D.A. Cell cycle regulation and hematologic disorders. In Beutler, E. et al. (Eds.):Williams Hematology 8 th Edition (McGraw Hill BK CO), pp , Vorträge und Poster: 1. Digel, W., Schmid, M., Buck, C., Stefanic, M., Schöniger, W., Heimpel, H. Porzsolt, F. Differential effects of interferon alpha and gamma of neoplastic B-cells in chronic lymphocytic leukemia. Ann. Haematol., 23:56, Schmid, M., Merk, B., and Porzsolt, F. Cyclosporin A inhibits cytokine induced cell growth in B-chronic lymphocytic leukemia. Ann. Haematol., 26:44, Porzsolt, F., Schmid, M., Staib, G., and Schrezenmaier, H. Paracrine regulation of B-cell growth in hairy cell leukemia. Rec. Adv. Chemother., Suppl. 1, , Schmid, M., Merk, B., Lawrenz, K., and Porzsolt, F. Levels of soluble intercellular adhesion molecule-3 (sicam-3) are increased in progressive stage of chronic lymphocytic leukemia and multiple myeloma. I. Wilsede- Chernobyl Meeting in Gomel, Belarus, September, Funke, I., Schmid, M., Clement, H.J., Merk, B., Stohlmann, G., Lesslauer, W., Prümmer, O., Heimpel, H. Investigation of the expression of p55 and p75 TNF receptors in B-chronic lymphocytic leukemia using polymerase chain reaction (PCR). Onkologie, 17 (Suppl. 2): Funke, I., Schmid, M., Prümmer, O., Gallati, H., and Porzsolt, F. TNF receptor (p55, p75) mrna expression circulating p55, p75 and TNF-a in stable and progressive B-CLL. Onkologie, 17 (Suppl. 2): Schmid, M., Lawrenz, K., Funke, I., Demeter, J., and Heimpel, H. Soluble intercellular adhesion molecule (sicam-) is a marker for disease progression and follow up of treatment in patients with B-chronic lymphocytic leukemia. Blood, 87 (Suppl. 1): 256, Schmid, M., Linortner, S., Hübinger, G., and Bergmann, L. The novel tumor suppressor gene candidate suppressin is downregulated in colon cancer cell lines by hypermethylation of CpG islands. Blood, 94 (Suppl. 1), 190b,1999.

8 9. Schmid, M., Bergmann, L., Sen, M., Rosenbach, M. D., and Carson, D.A. Identification of a new transcript on chromosome 9p21 in the p14 ARF region. Blood, 94 (Suppl. 1), 189b, Schmid, M. Kiaa0537, a new tumor suppressor gene candidate is inactivated in human brain tumors. Beyond the identification of transcribed sequences: functional and expression analysis. 10 th Annual Workshop, Heidelberg, Hübinger, G., Maurer, U., Linortner, S., Schmid, M., Manegold, A., and Bergmann, L. (2000) Growth suppression of the chronic myeloid leukemia cell line K562 by ribozyme-mediated cleavage of the transcription factor wt1. Blood, 96 (Suppl. 1), 302a, Schmid, M., Linortner, S., Ruff H., and Doehner, H. KIAA0537, a new tumor suppressor gene candidate, is frequently deleted in human brain tumors. Proc. Am. Assoc. Cancer Res., 42:78 (#419), Schmid, M., Linortner, S., Ruff, H., and Döhner, H. Kiaa0537, a ser/thr kinase that is frequently inactivated in primary human brain tumors. Onkologie, 24(Sonderheft 6):63 (#238), Schmid, M., Ruff, H., Lehmann, K., Cottam, H., and Döhner, H. Frequent chromosomal aberrations on chromosome 9p21 in AML cell lines implications for specific antineoplastic therapy. Onkologie, 25(Sonderheft 4):162 (#573), Ruff, H., Döhner, H., Schmid, M. The ras/mek/erk pathway is a target for 5 -aza-2`-deoxycytidiene (5`AzaCdr) induced apoptosis in acute myeloid cell lines. Onkologie, 25(Sonderheft 4):255 (#903), Schmid, M., Ruff, H., Lehmann, H., Cottam, H., and Doehner, H. Adenylosuccinat-synthease and adenosine kinase inhibition as therapeutic targets in MTAP negative malignancies. The Hematol. J., 3 (Suppl. 1), 152, Schmid, M., Ruff, H., Lehmann, K., Fricke, U., Heimpel, H., and Doehner, H. Gene expression profile of erythroid colony forming cells in a ase of congenital dyserythropoietic anemia type II (CDA II). The Hematol. J., 3 (Suppl. 1), 77, 2002.

9 18. Schmid, M., Lehmann, K., Doehner, H., and Ruff, H. Identification of a specific methylation pattern in acute myeloid leukemia. The Hematol. J., 3 (Suppl. 1), 162, Goekbuget, N., Boehme, A., Freund, M., Herrmann, S., Horst, H., Schmid, M., Krauter, J., Zander, I., Hoelzer, D., the GMALL Study Group. New Treatment Options for Relapsed and Rapidly Progressive T-ALL and T-Lymphoblastic Lymphoma (LBL). Blood, 100 (Suppl. 1), 765a, Ottmann, O.G., Wassmann, B., Gökbuget, N., Scheuring, U., Pfeifer, H., Brück, P., Binckebanck, A., Reutzel, R., Giagounidis, A., Sellmann, L., Planker, M., Troll, K., Gerecke, U., Horst, H.A., Stelljes, M., Claus, B., Schmid, M., Gschaidmeier, and Hoelzer, D. Imatinib monotherapy versus chemotherapy as induction followed by Imatinib plus chemotherapy in elderly patients (> 55 y) with Philadelphia-positive acute lymphoid leukemias: A randomized phase II study. Onkologie, 26(Sonderheft 5):84 (#P550), Giagounidis, A.A.N., Germing, U., Haase, B., Schlegelberger, B., Schoch, C., Kreipe, H.H., Aivado, M., Strupp, C., Lübbert, M., Lipke, J., Fetscher, S., Wysk, J., Grabenhorst, U., Schmid, M., Grips, K., Kimmich, M., Burstedde, V., Ganser, A., and Aul, C. Treatment of the 5q-syndrome with all-trans-retinoic acid: A phase II study of the German MDS study group. Onkologie, 26(Sonderheft 5):116 (#P667), Liebisch, P., Eppinger, S., Schöpflin, C., Stehle, G., Munzert, G., Döhner, H., and Schmid, M. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Onkologie, 26(Sonderheft 5):122 (#P687), Schmid, M. Histonedeacetylase-Inhibitors and all-trans retinoic acid (ATRA) in myeloid leukemias. Vortrag im Rahmen der gemeinsamen Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, Basel 6. Oktober Goekbuget, N., Al-Ali, H., Atta, J., Brueck, P., Boehme, A., Freund, M., Gerhardt, A., Hermann, S., Horst, H., Kaufmann, M., Kotthoff, R., Koch, U., Krauter, J., Pfeifer, H., Schmid, M., and Hoelzer, D. Improved outcome

10 of poor prognostic relapsed/refractory T-ALL and T-lymphoblastic lymphoma (LBL) with compound GW506U78 followed by immediate stem cell transplantation (SCT). The Hematol. J., 4 (Suppl. 2), 266, Wassmann, B., Gökbuget, N., Brück, P., Reutzel, R., Giagounidis, A., Sellmann, L., Planker, M., Troll, K., Gerecke, U., Horst, H.A., Stelljes, M., Claus, B., Schmid, M., Gschaidmeier, H., Hoelzer, D., and Ottmann, O.G. A randomized phase II study comparing imatinib with chemotherapy as induction followed by imatinib plus chemotherapy in elderly patients (> 55 y) with Philadelphia-positive acute lymphoid leukemias. The Hematol. J., 4 (Suppl. 2), 267, Liebisch, L., Eppinger, S., Schoepflin, C., Stehle, G., Munzert, G., Doehner, H., and Schmid, M. CD44v6, a Target for Novel Antibody Treatment Approaches, Is Frequently Expressed in Multiple Myeloma and Associated with Deletion of Chromosome Arm 13q. Blood, 102 (Suppl. 1), 365b, Schmid, M., Lehmann, K., and Döhner, H. The role of adenosine and adenosine kinase in acute myeloid leukemias with methylthioadenosine phosphorylase (MTAP) inactivation. The Hematol. J., 5 (Suppl. 2), 36, Gökbuget, N., Reutzel, R., Fietkau, R., Hartmann, F., Kneba, M., Leimer, L., Neubauer, A., Nowrousian, M., Peyn, A., Raff, T., Schmid, M., Thiel, E., Hoelzer, D. New options for the treatment of T-lymphoblastic lymphoma (T-LBL) in adults. Onkologie, 27(Supplement 3):76 (#O371), Schmid, M., Fröhling, S., Schlenk, R.F., Döhner, H. Treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) with the histone deacetylase inhibitor valproic acid (VA) in combination with all-trans retinoic acid (ATRA). Onkologie, 27(Supplement 3):83 (#O393), Beck, C., Pachnio, A., Lehmann, K., Döhner, H., Kneba, M., Leoni, L.M., Schmid, M. Effect of the adenylosuccinat-synthetase (ASS) inhibitor L- alanosine and a new adenosine kinase (AK) inhibitor (HC-7) on MTAP

11 positive and MTAP negative pancreatic cancer SCID mouse xenografts. Onkologie, 27(Supplement 3):52 (#O450), Schmid, M., Rücker, F., Döhner, K., Schwänen, C., Ruf, S., Lehmann, K., Döhner, H. Aberrations of the chromosomal band 9p21 in primary and relapsed acute myeloid leukemias (AML). Onkologie, 27(Supplement 3):166 (#P712), Goekbuget, N., Thiel, E., Beck J., Griesinger, F., Hartmann, F., Jentsch- Ulrich, K., Knipp, S., Lipp, T., Messerer, D., Metzner, B., Rutjes, J., Schmid, M., Schwartz, S., Staib, P., Stelljes, M., and Hoelzer, D. Improved outcome in adult T-ALL by risk adapted treatment strategies. Blood, 104:196a, Hoelzer, D., Goekbuget, N., Beck, J., Burmeister, T., Giagounidis, A., Glasmacher, A., Pfeifer, H., Rieder, H., Schmid, M., Thiel, E., Wassmann, b., and Ottmann, O.G. Subtype adjusted therapy impoves outcome of elderly patients with acute lymphoblastic leukaemia (ALL). Blood, 104:747a, Gökbuget, N., Arnold, R., Atta, J., Brück, P., Herrmann, S., Horst, H., Kondakci, M., Kotthoff, R., Ottmann, O.G., Raff, T., Ratei, R., Schmid, M. Stadler, M., and Hoelzer, D. High single drug activity of compound GW506U78 in relapsed T-lymphoblastic leukemia (T-ALL) and T- lymphoblastic lymphoma (T-LBL) offers option for cure with stem cell transplantation. Haematologica, 90:157, Lübbert, M., Rüter, B., Schmid, M., Knipp, S., Germing, U., Dobbelstein, C., Eimermacher, H., Deschler, B., Claus, R., Schlenk, R., Ganser, A., Döhner, H., Schmoor, C., and Henß, H.Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study. Blood, 106:1852, Goekbuget, N., Baur, K-H., Beck, J., Diedrich, H., Lamprecht, M., Leimer, L., Lipp, T., Neteler, J., Reutzel, R., Rutjes, J., Schmid, M., Staib, P., Stelljes, M., and Hoelzer, D. Dexamethasone Dose and Schedule Significantly Influences Remission Rate and Toxicity of Induction Therapy

12 in Adult Acute Lymphoblastic Leukemia (ALL): Results of the GMALL Pilot Trial 06/99. Blood, 106:1832, Goekbuget, N., Arnold, R., Atta, J., Brück, P., Hermann, S., Horst, H., Kondakci, M., Kotthoff, R., Ottmann, O., Raff, T.,R Ratei, R., Schmid, M., Stadler, M., and Dieter Hoelzer, D. Compound GW506U78 Has High Single-Drug Activity and Good Feasibility in Heavily Pretreated Relapsed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T- LBL) and Offers the Option for Cure with Stem Cell Transplantation (SCT). Blood, 106:150, Kuendgen, A., Schmid, M., Knipp, S., Hildebrandt, B., Fox, F., Strupp, C. Steidl, C., Haas, R., Germing, U., Dohner, H., Gattermann, N. Results of a phase II trial with valproic acid (VPA) alone or in combination with all-transretinoic acid (ATRA) in 71 patients with myelodysplastic syndromes or SAML/MDS. Leuk. Res., 29:S66, Schlenk, R.F., Bommer, M., Schmid, M., Fröhling, S., Lehmann, K., Groner, S., Hann, R., Krauter, J., Döhner, K., Ganser, A., Göttlicher, M., and Döhner, H. Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG. Blood, 106:2800, Kuendgen, A., Schmid, M., Knipp, S., Czibere, A., Hildebrandt, B., Steidl, C., Haas, R., Germing, U., Doehner, H., and Gattermann, N. Valproic Acid (VPA) Achieves High Response Rates in Patients with Low- Risk Myelodysplastic Syndromes. Blood, 106: 789, Bullinger, L., Richter, M., Döhner, K., Rucker, F.G., Scholl, C., Fröhling, S., Schlenk, R.F., Pollack, J.R., Döhner, H.,and Schmid, M. In vitro and in vivo valproic acid response signatures in adult acute myeloid leukemia. Haematologica, 91:222, Schmid, M., Schwänen, C., Ruf, S., Döhner, h., Wessendorf, S. Small 9p21-deletions detected by matrix-cgh in Patients with adult acute lymphoblastic leukemia indicate poor prognosis. Haematologica, 91:245, 2006.

13 43. Viardot, A., Schwänen, C., Goekbuget, N., Hoelzer, D., Döhner, H., Wessendorf, S., and Schmid, M. Identification of Novel Recurrent Genomic Aberrations by Array-CGH in Adult Acute Lymphoblastic Leukemia. Blood, 108:4476, Bullinger, L., Döhner, K., Schlenk, R.F., Rücker, F.G. Pollack, J.R. Döhner, H., and Schmid, M. In Vitro and In Vivo Monitoring of Valproic Acid Effects on Gene Expression Signatures in Adult Acute Myeloid Leukemia. Blood, 108:2605, Viardot, A., Schwaenen, C., Gökbuget, N., Hoelzer, D., Ruf, S., Döhner, H., Weßendorf, S., Schmid, M. 9p21-deletions detected by array-cgh are the most frequent recurrent aberrations in adult acute lymphoblastic leukemia and may constitute agenomic risk factor. Onkologie, 29:6, Schwarz, K., Goede, J., Kohne, E., Schmid, M., Heimpel, H. Genetic heterogeneity in congenital dyserythropoietic anemia type I (CDA I). Onkologie, 29:10, Bullinger, L., Döjhner, K., Rücker, F., Schlenk, R., Pollack, J., Döhner, H., Schmid, M. Evaluation of histone deacetylase inhibitor function in adult acute leukemia by monitoring in vitro and in vivo valproic acid response signatures. Onkologie, 29:82, Wölfle, M., Nickolay, C., Lehmann, K., Döhner, H., Schmid, M. Promoterhypermethylation oft he O6-methylguanine-DANNmethyltransferase gene in patients with myelodysplasia. Onkologie, 29:106, Nickolay, C., Schmid, M., Seidel, J., Seitz, K., Richter, H.P., Döhner, H., Wölfle, M. Promotermythlation leads to a reduced expression of O6- methylguanine-dna-methyltransferase in high-grade glioma. Onkologie, 29:200, Russ, A.C., Dugas, M., Schmid-Fetzer, S.C., Schlenk, R.F., Pollack, J.R., Döhner, K., Schmid, M., Döhner, H., and Bullinger, L. Combined Analysis of Valproic Acid Induced MicroRNA and Gene Expression Changes in Acute Myeloid Leukemia. Blood, 110:869, 2007.

14 51. Gattermann, N., Schmid, M., Vassilieff, D., Rose, C., Della Porta, M.G., Finelli, C., Taylor, K., Seymour, J.F., Lee, J.W., Jakobs, P., Domokos, G., Hadler, D. Severe iron overload in patients with myelodysplastic syndromes (MDS) enrolled in a large study of deferasirox (Exjade, ICL670). Leuk. Res., 31: , Lübbert, M., Rüter, B., Claus, R., Schmid, M., Germing, U., Eimermacher, H., Ganser, A., Platzbecker, U., Galm, O., Brugger, W., Heil, G., Wijermans, P.W., Pfeifer, D., Schmoor, C., and Döhner, H. Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331 Multicenter Phase II Study. Blood, 110:300, Hoelzer, D., Hiddemann, W., Baumann, A., Döhner, H., Dührsen, U., Fietkau, R., Hansmann, M.L., Hüttmann, A., Irmer, S., Kaun, S., Kneba, M., Reichle, A., Schmid, M., Schmidt-Wolf, I., Thiel, E., Walewski, J., and Gökbuget, N. High Survival Rate in Adult Burkitt s Lymphoma/Leukemia and Diffuse Large B-Cell Lymphoma with Mediastinal Involvement. Blood, 110:518, Viardot, A., Schwaenen, C., Gökbuget, N., Hoelzer, D., Witzens-Harig, M., Döhner, H., Weßendorf, S., and Schmid, M. Identification of novel recurrent genomic aberrations by array-cgh in adult acute lymphoblastic leukemia. Haematologica, 92:4, Hoelzer, D., Hiddemann, W., Baumann, A., Döhner, H., Dührsen, U., Fietkau, R., Hansmann,L-M., Hüttmann, A., Irmer, S., Kaun, S., Kneba, M., Reichle, A., Schmid, M., Schmidt-Wolf, I., Thiel, E., Walewski, J., and Gökbuget, N. High cure rate of adult Burkitt s and other high grade NHL by the combination of short intense chemotherapy cycles with rituximab. Haematologica, 92:151, Hoelzer, D., Hiddemann, W., Baumann, A., Döhner, H., Dührsen, U., Fietkau, R., Hansmann, M., Hüttmann, A., Irmer, S., Kaun, S., Kneba, M., Reichle, A., Schmid, M., Schmidt-Wolf, I., Thiel, E., Walewski, J., Gökbuget, N. Short intensive chemotherapy combined with rituximab leads to high cure rate in adult Burkitt s lymphoma and other high-grade NHL. Onkologie, 30:39, 2007.

15 57. Lübbert, M., Schmid, M., Rüter, B., Germing, U., Rethwisch, V., Ganser, A., Platzbecker, U., Galm, O., Brugger, W., Wijermans, P. W., Schmoor, C., and Döhner, H. Continued Treatment with An Outpatient Maintenance Schedule of Decitabine in Older AML Patients Ineligible for Induction Chemotherapy: Results of the Phase II Multicenter Trial. Blood, 112:2965, Goekbuget, N., Baumann, A., Beck, J., Boos, J., Brueggemann, M., Diedrich, H., Hüttmann, A., Leimer, L., Lipp, T., Naumann, R., Mohren, M., Reichle, A., Schäfer-Eckart, K., Schmalzing, M, Schmid, M., Schmitz, N., Therwey, T., and Hoelzer, D. PEG-Asparaginase in Adult Acute Lymphoblastic Leukemia (ALL): Efficacy and Feasibility Analysis with Increasing Dose Levels. Blood, 112:302, Gattermann, N., Schmid, M., Della Porta, M., Taylor, K., Seymour, J., Habr, D., Domokos, G., Hmissi, A., Guerci-Bresler, A., and Rose, C. Efficacy and Safety of Deferasirox (Exjade ) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial. Blood, 112:633, Topp, M., Goekbuget, N., Kufer, P., Zugmaier, G., Degenhard, E., Neumann, S., Horst, H.A., Viardot, A., Schmid, M., Ottmann, O.G., Schmidt, M., Reinhardt, C., Baeuerle, P.A., Nagorsen, D., Hoelzer, D., and Bargou, R.C. Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study. Blood, 112:1926, Goekbuget, N., Arnold, R., Baumann, A., Beck, J., Diedrich, H., Freund, M., Hüttmann, A., Kneba, M., Kreuzer, K.A., Leimer, L., Lipp, T., Messerer, D., Naumann, R., Reichle, A., Rieder, H., Schäfer-Eckart, K., Schmalzing, M., Schmid, M., Schmitz, N., Serve, H., Stelljes, M., Thiel, E., and Hoelzer, D. General Condition and Early Complications Have in Addition to

16 Disease- Specific Factors a Significant Impact on Outcome - Prognostic Factors Revisited in 1657 Adult ALL Patients (15 55 years). Blood, 112:1927, Schmid, M. Intrathekale Therapie von Meningeosen Fallbeispiele -. Deutsche Gesellschaft für Senologie, Stuttgart, Schmid, M. Therapie der Meningeosis carcinomatosa/lymphomatosa mit liposomalem Cytarabin - Fallberichte 27. Deutscher Krebskongress, Berlin, Hoelzer, D., Huettmann, A.M., Kaul, F., Irmer, S., Jaeckel, N., Mohren, M., Lipp, T., Wendelin, K., del Valle, F., Schmid, M., Thiel, E., Brueggemann, M., Kneba, M., and Goekbuget, N. Immunochemotherapy with rituximab in adult CD20+ B-precursor ALL improves molecular CR rae and outcome in standard risk (SR) as well as in high risk (HR) patients mit SCT. Haematologica; 94:195, Schmid, M. Aktuelle Therapie der Myelodysplastischen Syndrome. 2. Transalpines onkologisches Symposium, Herrsching, Schmid, M., Iron chelation therapy in MDS, Madrid, Spanien, Topp, M.S., Goekbuget, N., Kufer, P., Zugmaier, G., Klinger, M., Degenhard, E., Neumann, S., Horst, H.A., Raff, T., Viardot, A., Schmid, M., Ottmann, O., Burmeister, T., Schmidt, M., Reinhardt, C., Einsele, H., Baeuerle, P.A., Nagorsen, D., Riethmüller, G., Hoelzer, D., and Bargou, R.C. Blinatumomab (anticd19 BITE ) for targeted therapy of minimal residual disease (MRD) in patients with B-precursor acute lymphoblastic leukemia (ALL): update of an ongoing phase II study. Haematologica; 94:195, Gökbuget, N., Baumann, A., Beck, J., Boos, J., Brueggemann, M., Diedrich, H., Hüttmann, A., Leimer, L., Lipp, T., Naumann, R., Mohren, M., Reichle, A., Schäfer-Eckart, K., Schmalzing, M., Schmid, M., Schmitz, N., Therwey, T., and Hoelzer, D. PEG- Asparaginase in adult acute lymphoblastic leukemia (ALL): efficiacy and feasibility analysis with focus on liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) study 07/2003. Haematologica; 94:445, 2009.

17 69. Cucuianu, A.M., Dima, D., Dohner, H., Dohner, K., Schmid, M., Schlenk, R., and Petrov, L. The role of cytogenetics and molecular genetics in the management of acute myeloid leukemia. The experience of the hematology clinic Cluj-Napoca, Romania. Haematologica; 94:554, Schmid, M., Schöpflin, C., and Bommer, M. Cerebrospinal fluid pleocytosis an a diagnostic challenge discriminating reactive from malignant cells using flow cytometry. Haematologica; 94:644, Topp, M., Goekbuget, N., Kufer, P., Zugmaier, G., Klinger, M., Degenhard, E., Neumann, S., Horst, H., Raff, T., Viardot, A., Schmid, M., Ottmann, O., Burmeister, T., Schmidt, M., Reinhardt, C., Einsele, H., Baeuerle, P., Nagorsen, D., Riethmüller, G., Hoelzer, D., Bargou, R. C. Blinatumomab (Anti-CD19 BiTE ) for targeted therapy ofminimal residual disease (MRD) in patients with Bprecursor acute lymphoblastic leukemia (ALL): Update of an ongoing phase II study. Onkologie, 32:85, Schmid, M., Ganser, A., Platzbecker, U., Beris, P., Linkesch, W., Habr, D., Domokos, G., Leismann, O., Gattermann, N. Efficacy and Safety of Deferasirox (Exjade ) during 1 Year of Treatment in Transfusion- Dependent Patients with Myelodysplastic Syndromes: Overall and Austrian/German/Swiss Results from EPIC Trial. Onkologie, 32:128, Bommer, M., Nagy, A., Schöpflin, C., Schmid, M. Cerebrospinal fluid pleocytosis combined use of morphology and flow cytometry improves diagnostic yield. Onkologie, 32:54, Hoelzer, D., Thiel, E., Arnold, R., Beck, J., Beelen, D. W., Bornhäuser, M., Bunjes, D., Ditz, D., Dührsen, U, Finke, J., Horst, H.A., Kobbe, G., Kolb, H.J., Kreuzer, K.A., Kröger, N., Lipp, T., Schaich, M., Schmid, M., Schwartz, S., Schwerdtfeger, R., Serve, H., Stuhlmann, R., Wendelin, K., Scheid, C., and Gökbuget, N. Successful Subtype Oriented Treatment Strategies in Adult T-All; Results of 744 Patients Treated in Three Consecutive GMALL Studies. Blood, 114:324, 2009.

18 75. Schmid, M., Cappellini, M.D., Porter, J.B., Greenberg, P.L., Lawniczek, T., Glaser, S., Dong, V., and Gattermann, N. Safety of Deferasirox (Exjade ) in Myelodysplastic Syndromes (MDS) and Non-MDS Patients with Transfusional Iron Overload: A Pooled Analysis Focusing On Renal Function. Blood, 114:1768, Gattermann, N., Schmid, M., Guerci-Bresler, A., Della Porta, M., Taylor, K., Habr, D., Domokos, G., Roubert, B., and Fenaux, P. Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade ) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes. Blood, 114:3803, Schmid, M., Guerci-Bresler, A., Della Porta, M., Taylor, K., Habr, D., Domokos, G., Roubert, B., Rose, C., and Gattermann, N. Deferasirox (Exjade ) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS). Blood, 114:3806, Lübbert, M., Rüter, B.H., Schmid, M., Claus, R., Germing, U., Rethwisch, V., Ganser, A., Platzbecker, U., Galm, O., Brugger, W., Heil, G., Hackanson, B., Deschler, B., Wijermans, P.W., Schmoor, C., and Döhner, H. Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study. Blood, 114: 4141, Topp, M.S., Zugmaier, G., Goekbuget, N., Kufer, P., Goebeler, M., Klinger, M., Degenhard, E., Baeuerle, P.A., Schmidt, M., Nagorsen, D., Neumann, S., Horst, H.A., Raff, T., Viardot, A., Stelljes, M. Schmid, M., Ottmann, O.G., Burmeister, T., Einsele, H., Riethmueller, G., Hoelzer, D., and Bargou, R.C. Report of a Phase II Trial of Single-Agent BiTE Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL). Blood, 114:840, 2009.

19 80. Schmid, M. Iron overload in elderly MDS patients Diagnosis and treatment. Congress of the International Society of Geriatric Oncology (SIOG), Berlin, Schmid, M. Iron chelation therapy in MDS What have we learned recently? European Hematology association (AHA) Satelitten-Symposium, Berlin, Schmid, M. Optimal management of iron toxicity. Global Iron Summit (GIS), London, Schmid, M., Guerci-Bresler, A., Della Porta, M., Taylor, K., Habr, D., Domokos, G., Roubert, B., Rose, C., Gattermann, N. Efficacy and safety of deferasirox (Exjade ) in chelation-naive and previously chelated patients with transfusion-dependent myelodysplastic syndromes (MDS). Leuk. Res., 33: , Gattermann, N., Schmid, M., Guerci-Bresler, A., Della Porta, M., Taylor, K., Habr, D., Domokos, G., Roubert, B., Fenaux, P. Reduction in serum ferritin (SF) is associated with improvement in liver transaminase levels during treatment with deferasirox (Exjade ) in ironoverloaded patients with myelodysplastic syndromes (MDS). Leuk. Res., 33: , Schmid, M., Kiehne, U., Hilgendorf, I., Krammer-Steiner, B., Strick, H., Wiese, B., Heidenreich, F., Bommer, M. Liposomal cytarabine is effective in the treatment of neoplastic meningitis in patients with hematological disorders or solid tumors. Onkologie, 33:55, Bargou, R.C., Zugmaier, G., Goekbuget, N., Neumann, S., Horst, H., Raff, T., Brueggemann, M., Viardot, A., Schmid, M., Schaich, M., Stelljes, M., Goebeler, M., Pfeifer, H., Ottmann, O., Burmeister, T., Degenhard, E., Schmidt, M., Einsele, H., Kufer, P., Klinger, M., Nagorsen, D., Hoelzer, D., and Topp, S. Prolonged leukemia free survival following blinatumomab (anti-cd19 BITE) treatment of patients with minimal residual disease (MRD) of B precursor ALL: updated results of a phase II study. Haematologica; 95:250, Schmid, M. Deferasirox in der Behandlung der sekundären Eisenüberladung - Aktuelle Daten 29. Deutscher Krebskongress, Berlin, 2010.

20 88. Schmid, M. Optimal management of iron toxicity: MDS Global Iron Summit (GIS), Prag, Schmid, M. Lower risk MDS patients: role of iron chelation therapy. Global Iron Summit (GIS), London, Schmid, M. Myelodysplastische Syndrome. Aktuelle Therapie und Diagnostik. 35. Oberstaufener Symposium für Praktische Onkologie, Wunderlich, A.P., Cario, H., Schmid, M., and Juchems, M. Estimation of Liver Iron Content with different MRI methods. ISMRM annual Meeting, Stockholm, May, 2010.